A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Inclusion Criteria:

Confirmed diagnosis urothelial carcinoma of the bladder (Recurrence of prior NMIBC biopsy or pathology must be obtained within 12 months prior to enrollment. First time NMIBC biopsy within 6 months of screening. MIBC allowed if demonstrated pathologically)
Have no evidence of metastatic disease
Adequate bone marrow, renal, and hepatic function

Exclusion Criteria:

Any additional malignancy that requires active treatment. Exceptions include:

Basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy with evidence of remission for at least 1 year.
In situ cervical cancer treated and with at least 1 year without recurrence.
Any other subject felt appropriate by the Investigator upon discussion with trial's Medical Monitor.
Used an investigational drug or medical device within 30 days or 5 half-lives (whichever is longer) of Visit 1 or be concurrently enrolled in another investigational trial.
Active bacterial, fungal, or viral infections - all prior infections must have resolved following optimal therapy and subject must be off all systemic anti-infective agents.
Chronic active hepatitis B or C and HIV.